Drug-eluting stents: A systematic review and economic evaluation

Health Technology Assessment

Volumn 11, Issue 46, 2007, Pages

  Hill, R A ^a   Boland, A ^a   Dickson, R ^a   Dundar Y ^a   Haycox, A ^b   McLeod, C ^a   Mota, R Mujica ^a   Walley, T ^a   Bagust, A ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; DEXAMETHASONE; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; TACROLIMUS; TICLOPIDINE; TIROFIBAN; ZOTAROLIMUS;

CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG RELEASE; ECONOMIC EVALUATION; EMBASE; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MEDLINE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; REVIEW; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOSIS; ECONOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; TREATMENT OUTCOME; UNITED KINGDOM;

DRUG-ELUTING STENTS; GREAT BRITAIN; HUMANS; MODELS, ECONOMIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 38049020953     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11460     Document Type: Review

References (169)

1. National Institute for Health and Clinical Excellence. Final scope - ischaemic heart disease - coronary artery stents (review). 2005. URL: http://www.nice.org.uk/pdf/Stents_FinalScope_160205.pdf. Accessed 21 February 2005.
2. Hill R, Bagust A, Bakhai A, Dickson R, Dundar Y, Haycox A, et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004;8(35).
3. National Institute for Clinical Excellence. Guidance on the use of coronary artery stents. Technology Appraisal Guidance No. 71. London: National Institute for Clinical Excellence; 2003.
4. Peterson S, Peto V, Scarborough P, Rayner M. Coronary heart disease statistics. London: British Heart Foundation; 2005.
5. ACC/AHA. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Dallas, TX: American College of Cardiology and American Heart Association; 2002.
6. British Heart Foundation. URL: http://www.heartstats.org/ homepage.asp?id=6
7. Hoffman SN, TenBrook JA, Wolf MP, Pauker SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 2003;41:1293-304.
8. Nathoe HM, van Dijk D, Jansen EWL, Suyker WJL, Diephuis JC, van Boven W-J, et al. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med 2003; 348:394-402.
9. Rose EA. Off-pump coronary-artery bypass surgery. N Engl J Med 2003;348:379-80.
10. Ludman PF. on behalf of the Council of the British Cardiovascular Intervention Society (BCIS). BCIS audit returns adult interventional procedures 2003. York: British Cardiovascular Intervention Society; 2004.
11. British Cardiac Society, British Cardiovascular Intervention Society (BCIS). Submission document for NICE re-appraisal of coronary stenting 2002/2003. London: NICE; 2002.
12. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-47.
13. Hill RA, Dundar V, Bakhai A, Dickson R, Walley T. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 2004; 25:902-19.
14. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-91.
15. Shafiq N, Malhotra S, Pandhi P, Grover A, Uboweja A. A meta-analysis of clinical trials of paclitaxel- and sirolimus-eluting stents in patients with obstructive coronary artery disease. Br J Clin Pharmacol 2005;59:94-101.
16. Katritsis DG, Karvouni E, Ioannidis JP. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 2005; 95:640-3.
17. Kong DF. Drug-eluting stents reduce restenosis rates and major adverse cardiac events, but not mortality, in patients undergoing percutaneous coronary intervention. Evid Based Healthcare Public Health. 2005;9:16-19.
18. Meads C, Cummins C, Jolly K, Stevens A, Burls A, Hyde C. Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review. Health Technol Assess 2000;4(23).
19. Health Outcomes Data Repository (HODaR). URL: http://www.hodar.co.uk/
20. Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S. The Routine Collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 2005;8:581-90.
21. Dundar Y, Dodd S, Dickson R, Walley T, Haycox A, Williamson PR. Comparison of conference abstracts and presentations with full-text articles in the health technology assessments of rapidly evolving technologies. Health Technol Assess 2006;10(5).
22. Khan K, Ter Riet G, Glanville J, Sowdon A, Kleijnen J. Undertaking systematic reviews of research on effectiveness. CRD's guidance for carrying out or commissioning reviews. CRD Report No. 4. 2nd ed. York: Centre For Reviews and Dissemination, University of York; 2001.
23. Comité d'Evaluation et de Diffusion des Innovations Technologiques. Drug-eluting coronary stents - systematic review, expert panel. Paris: Secreteriat Scientifique Du Credit; 2002.
24. Doggrell SA. Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis. Expert Opin Pharmacother 2004;5:2209-20.
25. Doggrell SA. Sirolimus- versus paclitaxel-eluting stents in patients with stenosis in a native coronary artery. Expert Opin Pharmacother 2004;5:1431-4.
26. Lesiak M, Rzezniczak J, Baszko AM, Pyda MA, Grajek S, Mularek T, et al. Implantation of sirolimus-eluting stents in patients with higher risk of restenosis. One-year follow-up of 100 patients. Folia Cardiol 2004;11:505-11 (in Polish).
27. Liu X, De Scheerder I, Desmet W. Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis. Expert Rev Cardiovasc Ther 2004:2: 653-60.
28. Hernandez J, Burgos V, Gonzalez-Enriquez S, Zueco MCJ, Figueroa A, Colman T. Sirolimus-eluting stents to treat lesions with a high risk of restenosis. Six-month clinical follow-up in the first 100 patients. Rev Esp Cardiol 2004;57:116-22.
29. Keller PF, Ibrahim R, Tardif JC. The drug-based pipeline against restenosis. Expert Opin Emerg Drugs 2005;10:67-86.
30. Unidad de Evaluacion de Tecnologias S. Implementation of the drug eluting stent registry in Madrid (project).
31. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
32. Grube E. SPIRIT FIRST. Washington, DC: CRT; 2005.
33. Serruys PW, Homsy C, Meskini N. SPIRIT FIRST clinical trial: a clinical evaluation of the guidant MULTI-LINK VISION-E-(R) RX Drug Eluting Stent System in the treatment of patients with de novo native coronary artery lesions. Am J Cardiol 2004;94(6A):70E.
34. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. IAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
35. Grube E, Silber S, Hauptmann KE, Buellesfeld L, Mueller R, Lim V, et al. Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol 2005; 96:79.
36. Bullesfeld L, Gerckens U, Muller R, Grube E. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions - first results of both the clinical and angiographic 18 month follow-up of TAXUS I. Z Kardiol 2003;92:825-32.
37. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108: 788-94.
38. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, et al. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents - insights from the randomized TAXUS II trial. Circulation 2005; 111:900-5.
39. Serruys PW, Degertekin M, Tanabe K, Russell ME, Guagliumi G, Webb J, et al. Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation 2004:109:627-33.
40. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172.
41. Dangas G, Ellis SG, Shlofmitz R, Katz S, Fish D, Martin S, et al. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coll Cardiol 2005;45:1186.
42. Caputo R, Cox DA, Popma JJ, Hermiller J, O'Shaughnessy C, Mann JT, et al. Paclitaxel-eluting stents reduce need for subsequent coronary artery bypass graft surgery by changing the incidence and pattern of restenosis. Am J Cardiol 2004;94:211E-212E.
43. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV Trial. Circulation 2004;109:1942-7.
44. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
45. Stone GW, Ellis SG, Cox DA, Peters S, Lim VYT. Trial finds paclitaxel-eluting stents reduce restenosis over bare metal stents in coronary artery disease. Evid Based Cardiovasc Med 2004; 8:151-5.
46. Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, Albin G, et al. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1165.
47. Moses JW, Mehran R, Nikolsky E, Lasala JM, Corey W, Albin G, et al. Paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. Am J Cardiol 2004; 94:72E-73E.
48. Nikolsky E, Kosinski E, Mishkel G, Kimmelstiel C, McGarry TF, Mehran R, et al. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). Am J Cardiol 2005;95:709-15.
49. Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, et al. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol 2005; 45:1180.
50. Popma JJ, Ellis SG, Cox D, Hermiller J, O'Shaughnessy C, Mann JT, et al. Late quantitative angiographic results following treatment with a polymer-based paclitaxel-eluting stent compared with a bare metal stent in patients with de novo coronary disease: the TAXUS-IV angiographic results. J Am Coll Cardiol 2004;43:87A.
51. Costa RA, Lansky AJ, Tsuchiya Y, Cristea E, Tarawalli M, Sanchez R, et al. Impact of female sex on outcomes after paclitaxel-eluting stent implantation in patients with de Novo coronary lesions: results of the TAXUS IV trial. Am J Cardiol 2004;94:204E-205E.
52. Ellis S. TAXUS V trial global results: expanding the randomized data. Orlando, FL: American College of Cardiology; 2005.
53. Pache J, Dibra A, Mehilli J, Dirschinger J, Schomig A, Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 2005;26:1262-8.
54. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-15.
55. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Alfonso F, Goicolea J, Fernandez-Aviles F, et al. Sirolimus-eluting stent to prevent restenosis after stenting in diabetic patients with de novo coronary stenoses: The DIABETES (diabetes and sirolimus eluting stent) trial: 9-month angiographic results. Am J Cardiol 2004;94:75E.
56. Schofer J, Breithardt G, Wijns W, Gershlick AH, Rubino P, Simon R, et al. E-SIRIUS: 2-year clinical follow-up in patients with de-novo lesions treated with sirolimus-eluting stents. Presented at the European Cardiovascular Society Congress, Munich, 1 September 2004.
57. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362:1093-9.
58. Morice MC, Serruys P, Costantini C, Wuelfert E, Wijns W, Fajadet J, et al. Two-year follow-up of the RAVEL study: a randomized study with the sirolimus-eluting Bx VELOCITY stent in the treatment of patients with de-novo native coronary artery lesions. J Am Coll Cardiol 2003;41:32A.
59. Morice MC. Sirolimus-eluting stents for coronary revascularization. Cardiol Rev 2003;20(5):36-9.
60. Cordis. RAVEL Trial - 2 year clinical follow-up. Cordis submission to NICE; 2003.
61. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents - three-year results of the RAVEL trial. Circulation 2005;111:1040-4.
62. Regar E, Serruys PW, Bode C, Holubarsch C, Guermonprez JL, Wijns W, et al. Angiographic findings of the multicenter randomized study with the sirolimus-eluting Bx velocity balloon-expandable stent (RAVEL) - sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002;106:1949-56.
63. Fajadet J, Perin M, Hayashi EB, Colombo A, Schuler G, Barragan P, et al. 210-day follow-up of the RAVEL study: a randomized study with the sirolimus-eluting Bx VELOCITY balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. J Am Coll Cardiol 2002;39:20A.
64. Regar E, Sousa J, Morice MC, Fajadet J, Perin M, Ban Hayashi E, et al. Sirolimus-coated coronary stents prevent restenosis in diabetics. A subgroup analysis of the randomised, multi-centre RAVEL study. Z Kardiol 2002;91 (Suppl 1):I/65.
65. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 2002;106:798-803.
66. Cordis. Manufacturer submission to NICE. Drug eluting stents for prevention of restenosis, including review of coronary artery stents for ischaemic heart disease. London: National Institute for Clinical Excellence; 2002.
67. Kelaebk H, Thuesen L, Helqvist S, Kløvgaard L, Jørgensen E, Saunamäki K, et al. Randomised multicentre comparison of sirolimus vs bare metal stent implantation in complex coronary artery disease. 2005. TCTMD web presentation: www.tctmd.com/csportal/appmanager/ TCTMD/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon=756734
68. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Alfonso F, Hernandez-Antolin R, Banuelos C, et al. Sirolimus-eluting stent to prevent restenosis in diabetic patients with de novo coronary stenoses: the DIABETES (diabetes and sirolimus eluting stent) trial - one-month clinical follow- up. Circulation 2003;108:4.
69. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al. A randomized comparison of a sirolimus-eluting and an uncoated stent in the prevention of restenosis in small coronary arteries. Eur Heart J 2004;25 (Suppl. S):315.
70. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries - a randomized trial. JAMA. 2004;292:2727-34.
71. Holmes DR, Leon MB, Moses, JW Popma JJ, Cutlip D, Fitzgerald PJ, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial - a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109:634-40.
72. Leon M, Moses J, Holmes D, Kereiakes D, Cutlip D, Cohen S, et al. Long-term clinical benefit of CYPHER sirolimus-eluting coronary stents: three-year follow-up of the SIRIUS study. Presented at the American College of Cardiology Annual Scientific Sessions, Orlando, FL, 6-9 March 2005.
73. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-23.
74. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-8.
75. Sonoda S, Kataoka T, Morino Y, Hassan A, Perin EC, Wilensky RL, et al. Qualitative assessment of coronary lesions treated with sirolimus-eluting stents: serial intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol 2003;41:81A.
76. Sonoda S, Morino Y, Ako J, Terashima M, Hassan AHM, Bonneau HN, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation - serial intravascular ultrasound analysis from the SIRIUS trial. J Am Coll Cardiol 2004; 43:1959-63.
77. Sawhney N, Moses JW, Leon MB, Kuntz RE, Popma JJ, Bachinsky W, et al. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation 2004;110:374-9.
78. Popma JJ, Leon MB, Moses JW, Holmes Jr DR, Cox N, Fitzpatrick M, et al. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 2004;110:3773-80.
79. Li S, Fu X, Liu J, Wu W, Gu X, Ma N, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary small vessel lesions. Am J Cardiol 2004;94:218E.
80. Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 2005;293:2109-17.
81. Valgimigli M, Percoco G, Cicchitelli G, Ferrari F, Barbieri D, Ansani L, et al. High-dose BoluS TiRofibAn and sirolimus eluting STEnt versus abiciximab and bare metal stent in acute MYocardial infarction (STRATEGY) study - protocol design and demography of the first 100 patients. Cardiovasc Drugs Ther 2004;18:225-30.
82. Kaiser C, Brunner-La Rocca H, Buser P, Bonetti P, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a realworld setting: Randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-9.
83. Schluter M, Schofer J, Gershlick AH, Schampaert E, Wijns W, Breithardt G. Direct stenting of native de novo coronary artery lesions with the sirolimus-eluting stent - a post hoc subanalysis of the pooled E- and C-SIRIUS trials. J Am Coll Cardiol 2005;45: 10-13.
84. Morice MC, Serruys P, Costantini C, Wuelfert E, Wijns W, Fajadet J, et al. Three-year follow-up of the RAVEL study: a randomized study with the sirolimus-eluting Bx VELOCITY (TM) stent in the treatment of patients with de novo native coronary artery lesions. J Am Coll Cardiol 2004;43:87A-88A.
85. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL trial. Eur Heart J 2004;25:107-12.
86. Weissman NJ, Koglin J, Cox DA. Hermiller J, O'Shaughnessy C, Mann JT, et al. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1201.
87. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA. Hermiller J, et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: Analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1193.
88. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23.
89. Medtronic. Manufacturer submission to the National Institute for Health and Clinical Excellence. London: National Institute for Health and Clinical Excellence; 2005.
90. Rogers C. Emerging DES systems: Everolimus, ABT-578, and more. American College of Cardiology (late breaking trials). 2005. URL: http://www.tctmd.com/csportal/ShowBinary/BEA%20Repository/TCTMD%20Portal/ EPSlidePresPoolNew/2005/June2005Slides/Rogers_F05_R1330//pdfFile. Accessed 6 March 2005.
91. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. Risk of thrombosis with the use of Sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol 2005; 95:1469-72.
92. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126-30.
93. Hoffmann R, Langenberg R, Radke P, Franke A, Blindt R, Ortlepp J, et al. Evaluation of a high-dose dexamethasone-eluting stent. Am J Cardiol 2004;94:193-5.
94. Patti G, Pasceri V, Carminati P, D'Ambrosio A, Carcagni A, Di Sciascio G. Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 2005;95:502-5.
95. Liu XS, Huang YM, Hanet C, Vandormael M, Legrand V, Dens J, et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 2003;60: 172-8.
96. Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, et al. Prevention of testenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. Eur Heart J 2005;26:1475-81.
97. Bartorelli AL, Trabattoni D, Fabbiocchi F, Montorsi P, de Martini S, Calligaris G, et al. Synergy of passive coating and targeted drug delivery: the tacrolimus-eluting Janus CarboStent. J Intervent Cardiol 2003;16:499-505.
98. Occam International BV. AXXION. The eagle has landed! [product brochure]. 2004. URL: http://www.occam.nl/products/pdf_axxion.pdf. Accessed 12 September 2005.
99. Faxon DP. Bringing reality to drug-eluting stents. Circulation. 2004;109:140.
100. Gitt AK, Gottwik MG, Seabra-Gomes R, Cieslinski A, Hasdai D, Fioretti P, et al. Determinants for the use of drug-eluting stents in patients with acute coronary syndromes in Europe: results of the SHAKESPEARE Registry. Eur Heart J 2004;25(Suppl. S):524.
101. Lopez-Palop R, Moreu J, Fernandez-Vazquez F, Antolin RH. Spanish Registry of Cardiac Catheterization and Coronary Interventions. Thirteenth Official Report of the Working Group on Cardiac Catheterization and Interventional Cardiology of the Spanish Society of Cardiology (1990-2003). Rev Esp Cardiol 2004;57:1076-89.
102. Machecourt J, Danchin N, Lablanche JM. EVASTENT national registry: cost-effectiveness evaluation of sirolimus-eluting stent among diabetic and non-diabetic patients. Ann Cardiol Angeiol (Paris) 2004; 53(Suppl. 1):524 (in French).
103. Nakamura S, Bae HJ, Cahyadi HY, Udayachalerm W, Tresukosol D. Durable clinical benefit after sirolimus-eluting stent deployment in the outcomes of patients with unprotected left main coronary arteries: Multicenter registry 2-year results. Am J Cardiol 2004; 94(6A):4E.
104. Ribichini F, Tomai F, DiSciascio G, Paloscia L, Romano M, Carosio G, et al. Dexamethasone-eluting stent Italian registry in acute coronary syndromes. Preliminary results of the nationwide DESIRE study. Am J Cardiol 2004;94(6A):70E-71E.
105. Wacinski P, Bilodeau L, Gallo R, Tanguay JF, Ibrahim R, L'Allier P, et al. Drug-eluting stents in complex coronary lesion: comparison of sirolimus (Cypher) and paclitaxel (Taxus) stents in clinical practice. Montreal heart institute drug-eluting stents registry (MUST). Am J Cardiol 2004;94(6A): 133E-134E.
106. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy J-J, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005;294:819-25.
107. Windecker S, Remondino A, Eberli F, Wenaweser P, Togni M, Billinger M, et al. SIRTAX trial: a randomized comparison of SIRolimus with PacliTAXel eluting stents for coronary revascularization of all comers. 2005. URL: http://www.tctmd.com/csportal/ShowBinary/BEA%20Repository/ TCTMD%20Portal/EPSlidePresPool/ExpertPresentation_1114118642650// pdfFile. Accessed 27 July 2005.
108. Windecker S. A randomized comparison of sirolimus with paclitaxel eluting stents for coronary revascularization. SIRTAX Trial - design. 2005. URL: http://www.tctmd.com/csportal/ShowBinary/BEA%20Repository/ TCTMD%20Portal/EPSlidePresPool/ExpertPresentation_1114118642650// pdfFile. Accessed 27 July 2005.
109. Goy JJ, Stauffier JC, Siegenthaler M, Benoit A, Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology - the TAXi trial. J Am Coll Cardiol 2005;45:308-11.
110. Windecker S, Remondino A, Eberli F, Jüni P, Räber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005;353:653-62.
111. Beck D. ISAR-DIABETES: drug-eluting stents in diabetic patients [American college of cardiology 2005 meeting coverage]. 2005. URL: http://www.tctmd.com/meeting-news/one.html?news_item_id=4180. Accessed 27 July 2005.
112. Dibra A, Kastrari A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al. Paclitaxel-eluting or sirolimus-eluring stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353:663-70.
113. Kastrati A, Dibra A, Mehilli J, Pache J, Schühlen H, von Beckerath N, et al. ISAR-DIABETES: paclitaxel-eluting stent versus sirolimus-eluting stent for the prevention of restenosis in diabetic patients with coronary artery disease. 2005. URL: http://www.tctmd.com/ csportal/ShowBinary/BEA%20Repository/TCTMD%20Portal/EPSlidePresPool/ ExpertPresentation_1114118658633//pdfFile. Accessed 25 July 2005.
114. Suarez de Lezo J. Comparing CYPHER and TAXUS in high risk lesions. 2005. URL: http://www.tctmd.com/csportal/ShowBinary/BEA%2-Repository/ TCTMD%20Portal/EPSlidePresPoolNew/2005/Slides_May05/DeLezo_CRFACC05// pdfFile. Accessed July 2005.
115. Holmes D. SIRTAX and REALITY: a review of the results [in: Head-to-head DES trials: an overview of safety and efficacy]. 2005 URL: http://www.theheart.org/viewArticle.do?primaryKey=428961. Accessed 21 July 2005.
116. Head-to-head DES trials: an overview of safety and efficacy. 2005. URL: http://www.theheart.org/viewArticle.do?primaryKey=428961. Accessed 21 July 2005.
117. Morice MC. REALITY: a prospective, randomized, multi-center comparison study of the CYPHER sirolimus-eluting and TAXUS paclitaxel-eluting stent systems. 2005. URL: http://www.tctmd.com/csportal/ShowBinary/ BEA%20Repository/TCTMD%20Portal/EPSlidePresPool/ ExpertPresentation_1111621634470//pdfFile. Accessed 28 July 2005.
118. KiWiMed/Translumina. Manufacturer submission to the National Institute for Health and Clinical Excellence. London: National Institute for Health and Clinical Excellence; 2005.
119. Cordis Johnson and Johnson Medical Ltd. Manufacturer submission to the National Institute for Health and Clinical Excellence. London: National Institute for Health and Clinical Excellence; 2005.
120. Bagust A, Grayson A, Palmer A, Perry R, Walley T. Cost-effectiveness of drug-eluting coronary artery stenting in a UK setting: cost utility study. Heart 2006;92:68-74.
121. Cohen DJ, Bakhai A, Shi CX, Githiora L, Lavelle T, Berezin RH, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses - results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation 2004; 110: 508-14.
122. AETMIS. An economic analysis of drug eluting coronary stents. A Quebec perspective. Quebec: Artemis; 2004.
123. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol 2004;43:513-18.
124. Shrive FM, Manns BJ, Galbraith PD, Knudtson ML, Ghali WA. Economic evaluation of sirolimus-eluting stents. Can Med Assoc J 2005; 172:345-51.
125. van Hout BA, Serruys PW, Lemos PA, van den Brand M, van Es GA, Lindeboom WK, et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart 2005;91:507-12.
126. Gulizia M, Martelli E, Tamburino C, Tolaro S, Frasheri A, Grambanco F, et al. Impatto potenziale dello stent medicato nella pratica clinica siciliana. Ital Heart J 2004;5:630-8 (in Italian).
127. Tarricone R, Marchetti M, Lamotte M, et al. What reimbursement for coronary revascularisation with drug eluting stents? Eur J Health Econ 2004;49: 309-16.
128. Mittmann N, Brown A, Seung S, Coyle D, Cohen E, Brophy JM, et al. Economic evaluation of drug eluting stents. Technology Report No. 53. Ottawa, Canada: CCOHTA; 2005. URL: https://www.ccohta.ca/publications/ pdf/272_drug_eluting_stents_tr_e.pdf
129. O'Donoghue J, Goulding L. Consumer price inflation since 1750. Econ Trends 2004;604:38.
130. Thomas M. Are drug eluting stents really worth the money? Heart 2006;92:5-7.
131. Drummond M, Jefferson T. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Patty. BMJ 1996;313:275-83.
132. Niemela K. MILESTONE II: a multicenter global observational registry with TAXUS EXPRESS2 paclitaxel eluting stent system. Presented at the TEAM Congress. 2004.
133. Biondi-Zoccai GGL, Agostoni P, Abbate A, Airoldi F, Colombo A. Critical role of bare-metal stent controls in trials of drug-eluting stents. Eur Heart J 2005;26:1686-7.
134. Oostenbrink J, Tangelder M, Van Hout BA, Buskins E, Algra A, Lawson J, et al. Cost-effectiveness of oral anticoagulants versus aspirin in patients with infrainguinal bypass grafting surgery. J Vasc Surg 2001;34:254-62.
135. Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier H, Schonberger J, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. The Arterial Revascularization Therapies Study Group. N Engl J Med 2001;344:1117-24.
136. Department of Health. NHS reference costs 2004. 14 March 2005. Available from: http://www.dh.gov.uk/PolicyAndGuidance/OrganisationPolicy/ FinanceAndPlanning/NHSReferenceCosts/fs/en
137. The SOS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 2002;360: 965-70.
138. Department of Health. NHS waiting list statistics. 2003. URL: http://www.dh.gov.uk/PublicationsAndStatistics/PressReleases/ PressReleasesNotices/fs/en?CONTENT_ID=4072677&chk=rDvxnz. Accessed 13 February 2004.
139. Walley T, Bagust A, Greyson T, Perry R. Are drug eluting stents worth the money? [Electronic Letter to Thomas, MR. Are drug eluting stents really worth the money? Heart 2005]. 2005. URL: http://heart.bmjjournals.com/cgi/eletters/hrt.2005.066316v1#775. Accessed 8 September 2005.
140. Ludman P. BCIS audit returns adult interventional procedures 2003. Presented at the BCIS Autumn Meeting, York, October 2004.
141. Jilaihawi H, Khan S, Kovac J. Low incidence of revascularisation of bare metal stents in the era of drug eluting stents: a single tertiary centre experience. Heart 2005;91(Suppl I):A5.
142. Agema WR, Monraats PS, Zwinderman AH, De Winter RJ, Tio RA, Doevendans PA, et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 2004;25:1163-70.
143. Ellis SG, Bajzer CT, Bhatt DL, Brener SJ, Whitlow PL, Lincoff AM, et al. Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization. Catheter Cardiovasc Interv 2004;63:135-40.
144. Wu A, Goss J, Maynard C, Stewart D, Xue-Qiao Z. Predictors of repeat revascularization after nonemergent, first percutaneous coronary intervention in the community. Am Heart J 2004;147:146-50.
145. Ghali WA, Knudtson ML, on behalf of the APPROACH Investigators. Overview of the Alberta provincial project for outcome assessment in coronary artery disease. Can J Cardiol. 16:1225-30.
146. Tung R, Kaul S, Diamond G, Shah P. Drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med 2006; 144:919.
147. Cordis Johnson and Johnson. Ongoing Cypher Trials: Cordis industry submission to NICE 2003. London: NICE; 2003.
148. Williams DO, Kereiakes DJ. Safety and efficacy of drug-eluting stents. Rev Cardiovasc Med 2005;6(Suppl. 1):S22-30.
149. Gershlick A. Drug eluting stents in 2005. Heart 2005; 91:iii24-iii31.
150. Gershlick AH, Lotan C, Urban P, Guyon P, Schofer J, Seth A, et al. Treatment of acute myocardial infarction with sirolimus-eluting coronary stents: midterm results from the e-CYPHER international registry. Am J Cardiol 2004;94(6A):208E.
151. Gruberg L. The German Cypher Registry. 2004. URL: http://www.medscape.com/viewarticle/489416. Accessed 3 August 2005.
152. Zahn R, Hamm C, Schneider S, Zeymer U, Nienaber C, Richardt G, et al. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent Registry). Am J Cardiol 2005;95: 1302-8.
153. Park SJ, Kim YH, Lee CW, Hong MK, Park SW, Gwon HC, et al. Multicenter prospective nonrandomized registry study for drug-eluting stents in very long coronary lesions (Cypher vs Taxus): long drug-eluting stent study. Am J Cardiol 2004;94: 134E.
154. DeScheerder I. Long term data with the Dexamet™ Stent. 2003. URL: http://www.tctmd.com/display/expert/pdf/72709/ DrScheerder-DEXAMET.pdf. Accessed March 2005.
155. Lemos PA, Serruys PW, Van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the 'real-world': the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry. Circulation 2004;109: 190-5.
156. Arampatzis CA, Hoye A, Lemos PA, Saia F, Tanabe K, Degertekin M, et al. Elective sirolimus-eluting stent implantation for multivessel disease involving significant LAD stenosis: one-year clinical outcomes of 99 consecutive patients - The Rotterdam experience. Catheter Cardiovasc Interv 2004;63:57-60.
157. Degertekin M, Arampatzis CA, Lemos PA, Saia F, Hoye A, Daemen J, et al. Very long sirolimus-eluting stent implantation for de novo coronary lesions. Am J Cardiol 2004;93:826-9.
158. Goy JJ, Urban P, Seydoux C, De Benedetti E, Stauffer JC. Use of sirolimus-eluting coronary stents in routine clinical practice. Catheter Cardiovasc Interv 2004;62:26-9; discussion 62.
159. Abizaid A. Lessons learned from real world TAXUS Registries: WISDOM, MILESTONE II and ARRIVE. 2004. URL: http://www.tctmd.com/csportal/ appmanager/tctmd/main?_nfpb=true&_pageLabel=TCTMDContent&hdCon= 757247. Accessed 16 March 2005.
160. Boston Scientific. Arrive 2 US Safety Registry. 2005. URL: http://www.bostonscientific.com/common_templates/ clinicalTrials.jsp?task=tskClinicalTrials.jsp§ionId= 2&relId=86,88&uniqueId=ABBF1981. Accessed 13 August 2005.
161. Abizaid A, Chan C, Kaul U, Patel T, Tan HC, Sinha N, et al. "Real world" evaluation of slow-release, polymer-based, paclitaxel-eluting TAXUS (TM) stents in native coronary arteries: the WISDOM international registry. Circulation 2003;108(17 Suppl. S 534):2436.
162. Boston Scientific. Olympic Registry. 2005. URL: http://www.bostonscientific.com/common_templates/ articleDisplayTemplate.jsp?task=tskPressRelease.jsp§ionId= 2&relId=24,25&uniqueId=ABPR5541&clickType= endeca&acceptedWarning=PR. Accessed 3 August 2005.
163. Chieffo A, Colombo A. Polymer-based paclitaxel-eluting coronary stents - clinical results in de novo lesions. Herz 2004;29:147-51.
164. Ong AT, Serrurys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez Granillo GA, et al. The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-stent evaluated at Rotterdam Cardiology Hospital (T-SEARCH) Registry. J Am Coll Cardiol 2005; 45: 1135-41.
165. Simonton CA, Brodie BR, Wilson BH. Drug-eluting stents for emerging treatment strategies in complex lesions. Rev Cardiovasc Med 2005;6 (Suppl. 1):S38-47.
166. Laskey W, Williams D, Vlachos H, Cohen H. Holmes D, King S, et al. Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the National Heart, Lung and Blood Institute (NHLBI) Dynamic Registry. Am J Cardiol 2001; 87:964-9.
167. Buellesfeld L, Grube E. ABT-578-eluting stents - the promising successor of sirolimus- and paclitaxel-eluting stent concepts? Herz 2004; 29: 167-70.
168. Fajadet J, Wijns W, Kuntz RE. ENDEAVOR II. A randomized trial to evaluate the safety and efficacy of the Medtronic AVE ABT-578 eluting driver coronary stent in de novo native coronary artery lesion. 12 month follow-up. In: Meredith I, Wijns W. ENDEAVOR I and II clinical program long term follow-up. 2005. URL: http://www.tctmd.com/ csportal/ShowBinary/BEA%20Repository/TCTMD%20Portal/EPSlidePresPoolNew/ 2005/Sept2005Slides/Meredith_Wijns_ESC05//pdfFile;jsessionid= Dpd2FTgqjsNdqDIrlgGCkwKQTn4P0mDnQjX22gbn5ppBTKIMmCJC!-1575633090. Accessed 7 September 2005.
169. Wood S. BASKET: DES cost-effective only in high-risk patients. 2005. URL: http://www.theheart.org/viewArticle.do?primaryKey=556107. Accessed 27 July 2005.